328 related articles for article (PubMed ID: 12975752)
1. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.
Steinbach WJ; Stevens DA; Denning DW
Clin Infect Dis; 2003 Oct; 37 Suppl 3():S188-224. PubMed ID: 12975752
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
Chandrasekar PH; Cutright JL; Manavathu EK
Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
[TBL] [Abstract][Full Text] [Related]
3. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
4. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
[TBL] [Abstract][Full Text] [Related]
6. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
7. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
Graybill JR; Bocanegra R; Gonzalez GM; Najvar LK
J Antimicrob Chemother; 2003 Oct; 52(4):656-62. PubMed ID: 12972452
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy.
Yokote T; Akioka T; Oka S; Fujisaka T; Yamano T; Hara S; Tsuji M; Hanafusa T
Ann Hematol; 2004 Jan; 83(1):64-6. PubMed ID: 14661114
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
10. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
Schwartz S; Ruhnke M; Ribaud P; Reed E; Troke P; Thiel E
Mycoses; 2007 May; 50(3):196-200. PubMed ID: 17472616
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
[TBL] [Abstract][Full Text] [Related]
12. Combined antifungal therapy in a murine infection by Candida glabrata.
Mariné M; Serena C; Pastor FJ; Guarro J
J Antimicrob Chemother; 2006 Dec; 58(6):1295-8. PubMed ID: 17012301
[TBL] [Abstract][Full Text] [Related]
13. [Curative treatment of invasive aspergillosis].
Dupont B
Pathol Biol (Paris); 1994 Sep; 42(7):688-93. PubMed ID: 7877863
[TBL] [Abstract][Full Text] [Related]
14. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula.
Serena C; Mariné M; Pastor FJ; Nolard N; Guarro J
J Antimicrob Chemother; 2005 Jun; 55(6):1020-3. PubMed ID: 15845779
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of micafungin for chronic pulmonary aspergillosis.
Izumikawa K; Ohtsu Y; Kawabata M; Takaya H; Miyamoto A; Sakamoto S; Kishi K; Tsuboi E; Homma S; Yoshimura K
Med Mycol; 2007 May; 45(3):273-8. PubMed ID: 17464848
[TBL] [Abstract][Full Text] [Related]
16. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.
Okugawa S; Ota Y; Tatsuno K; Tsukada K; Kishino S; Koike K
Scand J Infect Dis; 2007; 39(4):344-6. PubMed ID: 17454899
[TBL] [Abstract][Full Text] [Related]
17. Combination antifungal therapy: where are we now, and where are we going?
Marr K
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
[TBL] [Abstract][Full Text] [Related]
18. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies.
Steinbach WJ
Curr Drug Targets Infect Disord; 2005 Sep; 5(3):203-10. PubMed ID: 16181140
[TBL] [Abstract][Full Text] [Related]
19. Echinocandin antifungal drugs.
Denning DW
Lancet; 2003 Oct; 362(9390):1142-51. PubMed ID: 14550704
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of current drug therapies for invasive aspergillosis.
Traunmüller F; Popovic M; Konz KH; Smolle-Jüttner FM; Joukhadar C
Pharmacology; 2011; 88(3-4):213-24. PubMed ID: 21986253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
